NCT04245514
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
StatusActive, Not Recruiting
PhasePhase 2
SponsorSwiss Cancer Institute
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 17 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 31 words Show 4 more changesShow less
- Primary completion pushed from Jul 16, 2026 to Dec 7, 2026
- Secondary endpoints: details revised at 10 of 10 entries
- Study description expanded, about 11 words
- Publications: details revised at 1 of 1 entry
- Notable Primary completion date: Dec 2025 to Jul 16, 2026v20
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 13 of 13 sites
- Minor Site contacts updated at 1 of 13 sitesv18
- Minor Study sites: 12 to 13v17
Show 11 earlier versionsHide 11 earlier versions
Notable Primary completion date: Jun 2024 to Dec 2025v16 Show 4 more changesShow less
- Eligibility criteria expanded, about 41 words
- Study sites: 13 to 12
- Study completion date: Mar 2025 to Dec 2031
- Secondary endpoints: 9 to 10
- Notable Primary completion date: Oct 2023 to Jun 2024v15
- Minor Site contacts updated at 1 of 13 sitesv14
- Minor Site contacts updated at 1 of 13 sitesv11
- Minor Site contacts updated at 1 of 13 sitesv10
- Minor Start date changed from estimate of Jul 2020 to Jul 15, 2020v7
- Minor Study sites revised (13)v6
- Minor Start date: Jun 2020 to Jul 2020v5
- Minor Site details revised at 4 of 13 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 14 to 13
- Notable Start date: Mar 2020 to Jun 2020v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Event-free survival (EFS) at 12 months
Timeframe: at 12 months
Secondary (10)
Event-free survival (EFS)
Recurrence-free survival (RFS) after R0 resection
Overall survival (OS)
Objective response (OR) after neoadjuvant chemotherapy
OR after neoadjuvant immuno-radiotherapy
Show 5 moreShow less
Pathological Complete Response (pCR)
Local Major pathological response (MPR)
Overall Major pathological response (oMPR)
Nodal down-staging to < ypN2
Complete resection
Arms and interventions
Durvalumab with 3 RT cohortsExperimental
Patients will be allocated in a 1:1:1 ratio to the three radiotherapy regimens (Arm A: 20 x 2 Gy weekdaily, Arm B: 5 x 5 Gy weekdaily, and Arm C: 3 x 8 Gy q2d) using the minimization method with a random component (80% allocation probability) to reduce predictability of allocation according to the following stratification factor: T classification (T1-2 vs T3-4).
Drugs: Durvalumab
Radiation: Radiotherapy
Sites
13 sites in 2 countries
Switzerland 12, Germany 1